Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tomentosin SCHEMBL10028477 | 1.00 | KDR (0.58) | KDRMAPTRAB9APKMRECQL | |
| SCHEMBL10028473 | 0.82 | KDR (0.51) | KDRMAPTRAB9APKMRECQL | |
| SCHEMBL2553256 | 0.73 | KDR (1.00) | KDRMAPTRAB9APKMRECQL | |
| SCHEMBL29367155 | 0.73 | KDR (0.52) | KDRMAPTRAB9APKMRECQL | |
| SCHEMBL16202801 | 0.62 | LMNA (0.35) | — | |
| Carabrone SCHEMBL30046035 | 0.61 | NLRP3 (0.40) | MAPTRAB9ANPC1XBP1HTT | |
| SCHEMBL29410309 | 0.60 | MAPT (0.43) | KDRMAPTRAB9APKMRECQL | |
| SCHEMBL8629536 | 0.60 | MAPT (0.43) | KDRMAPTRAB9APKMRECQL | |
| SCHEMBL9240777 | 0.60 | MAPT (0.43) | KDRMAPTRAB9APKMRECQL | |
| SCHEMBL9242953 | 0.60 | MAPT (0.43) | KDRMAPTRAB9APKMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146282-A1 | QUANTIFICATION OF NUCLEIC ACIDS AND/OR ASSESSMENT OF THE STATUS OF NUCLEIC ACID DEGRADATION AND/OR INTEGRITY BY DIGITAL PCR | QIAGEN GMBH (DE) | 2026-05-28 | — | — | US | disclosed |
| EP-4735632-A1 | HIGH-ACCURACY QUANTIFICATION OF NUCLEIC ACIDS FROM PRE-DEFINED AMOUNTS OF CELLS USING PLATE-BASED DIGITIAL PCR | QIAGEN GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-3516072-B1 | METHOD FOR QUANTIFYING AND/OR DETECTING HUMAN MALE DNA | QIAGEN GMBH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-3512962-B1 | METHOD AND KIT FOR DETERMINING NUCLEIC ACID DEGRADATION | QIAGEN GMBH (DE) | 2026-02-11 | — | — | EP | disclosed |
| US-20260007131-A1 | HERBICIDAL COMPOSITION CONTAINING DIFLUOROBUTENOIC ACID AMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2026-01-08 | — | — | US | disclosed |
| US-20250380696-A1 | METHOD FOR CONTROLLING UNDESIRED PLANTS AND PROMOTING GROWTH OF USEFUL PLANTS | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2025-12-18 | — | — | US | disclosed |
| EP-4638790-A1 | METHOD OF NUCLEIC ACID QUANTIFICATION USED TO INCREASE DYNAMIC RANGE IN DIGITAL PCR | QIAGEN GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4608990-A1 | QUANTIFCATION OF NUCLEIC ACIDS AND/OR ASSESSMENT OF THE STATUS OF NUCLEIC ACID DEGRADATION AND/OR INTEGRITY BY DIGITAL PCR | QIAGEN GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4608991-A1 | DIGITAL AMPLIFICATION METHOD FOR QUANTIFYING AND/OR DETERMINING INTEGRITY OF HUMAN MALE DNA | QIAGEN GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4581154-A1 | FREEZE DRIED NUCLEIC ACID AMPLIFICATION MIXTURE | QIAGEN GmbH (DE) | 2025-07-09 | — | — | EP | disclosed |
| US-11384383-B2 | In vitro isolation and enrichment of nucleic acids using site-specific nucleases | DEPIXUS (FR) | 2022-07-12 | — | — | US | disclosed |
| US-20220211041-A1 | HERBICIDAL COMPOSITION | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2022-07-07 | — | — | US | disclosed |
| US-20220202018-A1 | HERBICIDAL COMPOSITION | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| EP-4018000-A1 | COMPOSITION AND METHOD FOR AMPLIFICATION OF STR LOCI | QIAGEN GmbH (DE) | 2022-06-29 | — | — | EP | disclosed |
| EP-4010494-A1 | RNA SEQUENCING METHOD FOR THE ANALYSIS OF B AND T CELL TRANSCRIPTOME IN PHENOTYPICALLY DEFINED B AND T CELL SUBSETS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-06-15 | — | — | EP | disclosed |
| US-11345952-B2 | Internal amplification control | QIAGEN GMBH (DE) | 2022-05-31 | — | — | US | disclosed |
| EP-3837379-B1 | METHOD OF NUCLEIC ACID ENRICHMENT USING SITE-SPECIFIC NUCLEASES FOLLOWED BY CAPTURE | DEPIXUS (FR) | 2022-05-18 | — | — | EP | disclosed |
| US-20220145357-A1 | METHOD OF NUCLEIC ACID ENRICHMENT USING SITE-SPECIFIC NUCLEASES FOLLOWED BY CAPTURE | DEPIXUS (FR) | 2022-05-12 | — | — | US | disclosed |
| EP-3977857-A1 | HERBICIDE COMPOSITION | Ishihara Sangyo Kaisha, Ltd. (JP) | 2022-04-06 | — | — | EP | disclosed |
| US-20220025451-A1 | KIT FOR DETERMINING NUCLEIC ACID DEGRADATION | QIAGEN GMBH (DE) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146282-A1 | QUANTIFICATION OF NUCLEIC ACIDS AND/OR ASSESSMENT OF THE STATUS OF NUCLEIC ACID DEGRADATION AND/OR INTEGRITY BY DIGITAL PCR | DNTT, POLL, GDA | KDR 4205/4885MAPT 3357/4885RAB9A 4187/4885 |
| US-20260007131-A1 | HERBICIDAL COMPOSITION CONTAINING DIFLUOROBUTENOIC ACID AMIDE COMPOUND | DDT, CBR1, DHCR24 | KDR 1824/4885MAPT 4537/4885RAB9A 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.